Joel Michael Maryles
Known title: DirectorCIK: 0001850990
Joel Michael Maryles's purchase track record
Joel Michael Maryles has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/24/2022 | CMMB | $1K | +15.0% | -28.6% | +1.6% |
| 3/18/2022 | CMMB | $4K | -25.9% | -33.0% | -13.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CMMB | ▲ Buy | Open Market | 400 | $1K | 5/24/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 33 | $91 | 5/24/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 500 | $2K | 3/18/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 500 | $2K | 3/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Chemomab Amends Merger Agreement for U.S. Redomiciliation
Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.
Chemomab Amends Merger Agreement for U.S. Redomiciliation. Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.